Brammer Bio investing $50M in gene-therapy facility

Gene therapy
(Your Genome)

A brand-new CDMO is pushing forward with plans to be a player in gene-based drug manufacturing with a new manufacturing facility in a U.S. biotech hub.

Lexington, MA-based Brammer Bio laid out its plans at the BIO International event in San Francisco, saying it will spend about $50 million to outfit and staff a 50,000-square-foot facility in its home city for production of late-stage and commercial-scale viral vector and cell-based therapies.

Brammer Bio expects the facility to be operating by Q2 of next year. The plan is to eventually add 200 employees to its workforce there.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Brammer Bio was formed in March through the merger of Brammer Biopharmaceuticals and Alachua, FL-based Florida Biologix, with the help of a capital infusion from Ampersand Capital Partners, Florida Biologix's majority owner.

"The Lexington facility will be equipped for largescale manufacturing with a focus on compliance in these emerging drug categories,” Richard Snyder, Brammer CSO, said in a statement.

The company also has 45,000 square feet of process development and Phase I/II clinical manufacturing space in Alachua, FL, and intends to double that.

As more and more of the specialty drugs being developed by biotech and pharma are gene-based therapies, Brammer joins Japan’s Fujifilm Diosynth Biotechnologies and others like Swiss CDMO Lonza, in hustling to build or expand facilities to manufacture them.

- read the announcement 

Related Articles: 
New player jumping into cell therapies manufacturing 
Merck to outfit $60M biologics plant for Fujifilm to use

Suggested Articles

Baxter Biopharma Services will spend $50 million to expand its facility in Bloomington, Indiana, to include fill-finish technology.

The FDA knocked India's Aurolife for chronic water leaks from its ceiling that may have contaminated multiple generic medicines.

Moderna and the EU have reached a supply deal for 160 million doses of the biotech's mRNA-based COVID-19 vaccine.